Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (10 mg/1000 mg and 5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Empagliflozin/metformin (Primary) ; Empagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 09 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Apr 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
- 16 Apr 2014 New trial record